Re­searchers are look­ing to solve PTSD. Could MD­MA-as­sist­ed ther­a­pies pro­vide an an­swer?

Due per­haps to prej­u­dice and prece­dent, the FDA and phar­ma­ceu­ti­cal in­dus­try have long shied away from test­ing con­trolled sub­stances as ther­a­pies for a range of hard-to-treat men­tal dis­or­ders. But the ice is thaw­ing, and a land­mark Phase III test for psy­che­del­ic MD­MA has turned out some promis­ing re­sults.

Eighty-eight per­cent of PTSD pa­tients who re­ceived three MD­MA-as­sist­ed talk ther­a­py ses­sions re­port­ed clin­i­cal­ly mean­ing­ful re­duc­tions in symp­toms com­pared with pa­tients who re­ceived place­bo (p=<0.0001), ac­cord­ing to da­ta from a Phase III study spon­sored by the Mul­ti­dis­ci­pli­nary As­so­ci­a­tion of Psy­che­del­ic Stud­ies (MAPS) un­veiled Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER